NCT02252263View on ClinicalTrials.gov

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 9, 2014

Primary Completion Date

October 10, 2017

Study Completion Date

October 10, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

DRUG

Lirilumab

DRUG

Urelumab

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University Of Pennsylvania, Philadelphia

21287

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

31008

Local Institution, Pamplona

43210

The Ohio State University, Columbus

97239

Oregon Health & Science University, Portland

Unknown

University Of Arkansas For Medical Sciences, Little Rock

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02252263 - A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma | Biotech Hunter | Biotech Hunter